The EU agrees to improve patients’ access to critical medicines

The European Union has reached a provisional agreement on its Critical Medicines Act, a significant legislative step aimed at bolstering the bloc's supply chain for essential pharmaceuticals. This development addresses persistent shortages of critical medicines, including antibiotics, vaccines, and insulin, which have impacted patients' access to vital treatments across Europe. The act signifies a proactive approach by the EU to enhance the resilience of its healthcare systems and ensure continuity of care for chronic and rare diseases. Key provisions of the Critical Medicines Act focus on strengthening procurement processes and fostering collaboration among member states. Public hospitals will now be mandated to consider supply security alongside medicine prices when making purchasing decisions, shifting the procurement paradigm. This measure aims to create more equitable access to medicines by encouraging joint purchasing initiatives and reducing reliance on single suppliers, thereby mitigating the risk of future shortages. The impact of this legislation is far-reaching, directly benefiting patients and consumers by promising improved availability of essential treatments. It also signals a broader trend within the EU towards greater self-sufficiency and strategic autonomy in critical sectors. By reinforcing the European pharmaceutical supply chain, the act contributes to the bloc's digital sovereignty goals by ensuring that essential services are not overly dependent on external factors.